Board
Screen
Heat
Cal
Watch
News
Blog
TV
Home
/
BNTX
Home
/
BNTX

NASDAQ
$90.22
$90.22

Overview

Price performance
Low
$88.25
High
$91.46
Market open. Last updated: Nov 4, 2026, 8:09 PM UTC
$
90.22
3.30 (3.80%)
Average, 50 days
$96.14
$96.89
Open
$89.00
Previous close
$86.92
52-week high
$124.00
Jan 22, 2026 (10 months ago)
52-week low
$79.52
Mar 10, 2026 (8 months ago)
13.46%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
22.66B
Volume
959 087
Total Return (3M)
-1.13%
Total Return (1Y)
-13.84%
—
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
DE
Website
biontech.com
Socials
About
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer. BNT113 is undergoing Phase 2 investigation for HPV-positive head and neck cancers. BNT114 is in Phase 1 for triple-negative breast cancer. BNT115 is also in Phase 1, targeting ovarian cancer. BNT116 is a preclinical candidate for non-small cell lung cancer. The company also pioneers personalized therapies that target neoantigens, such as Autogene cevumeran (BNT122), which is in Phase 2 for first-line melanoma and Phase 1a/1b for a range of solid tumors. Furthermore, its pipeline includes an mRNA-based intratumoral immunotherapy, SAR441000, currently in Phase 1 for solid tumors, as well as BNT141 and BNT142, also in Phase 1 for multiple solid tumors. BioNTech's portfolio extends to RiboCytokine therapies (BNT151, BNT152, and BNT153) aimed at solid tumors, and cutting-edge chimeric antigen receptor T-cell (CAR T-cell) immunotherapies like BNT211 for various solid tumors and BNT221 for other types of cancer. Immune checkpoint modulators, specifically GEN1046 and GEN1042, are also under Phase 1/2 clinical investigation for solid tumors. Beyond these, the firm is developing BNT321, an IgG1 monoclonal antibody in Phase 2 for pancreatic cancer, and BNT411, a small molecule immunomodulator candidate for solid tumors. Its broader scope encompasses preventative vaccines for illnesses like COVID-19 and Influenza, additional immunotherapies for infectious diseases, and protein replacement therapies designed for rare conditions. To advance its extensive pipeline, BioNTech has forged strategic partnerships with major pharmaceutical and biotechnology firms, including Genentech, Sanofi S.A., Genmab A/S, Pfizer Inc., Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Regeneron Pharmaceuticals, Inc. Established in 2008, BioNTech SE maintains its principal operations in Mainz, Germany.

Frequently asked questions

BNTX · BioNTech SE

01What is BioNTech SE stock price today?

The current price of BNTX is $90.22 — it has increased by 3.80% since the previous close. Data as of Nov 4, 2026.

02Is BioNTech SE stock price growing?

BNTX is up 1.27% over the past week, down 6.76% over the past month and down 13.81% over the past year. The price is below its 200-day moving average of $96.89.

03What is BNTX stock forecast?

Analysts' average 12-month price target for BNTX is $120.33, which implies 33.37% upside from the current price. Individual estimates range from $96.00 to $140.00.

04What do analysts say about BNTX stock?

Of the 21 analysts covering BioNTech SE, 1 rates it a strong buy, 13 rate it a buy and 7 rate it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

05What is BioNTech SE market cap?

BioNTech SE has a market capitalization of $22.66B. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

06What were BioNTech SE earnings last quarter?

In its most recent quarterly report, BioNTech SE posted earnings of $1.99 per share against an estimate of $0.757, beating expectations by 162.88%. Upcoming reports are listed in the earnings calendar.

07What is BioNTech SE revenue for the last quarter?

BioNTech SE reported revenue of $1.46B in its most recent quarter, which has decreased by 17.91% compared with the same quarter a year earlier. Analysts had expected $1.17B.

08Does BioNTech SE pay dividends?

BioNTech SE has not paid any dividends over the past year.

09Who are BioNTech SE competitors?

Companies most comparable to BioNTech SE include Genmab A/S, Incyte Corporation, TG Therapeutics, Inc., ImmunityBio, Inc. and Iovance Biotherapeutics, Inc.

10How volatile is BNTX stock?

In the latest trading session BNTX moved between $88.25 and $91.46, a range of 3.56% of its current price.

11Should I invest in BioNTech SE stock?

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of BioNTech SE shows a neutral rating today. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for BioNTech SE is strong sell. Technical ratings are indicators, not investment advice.

12What are BNTX stock 52-week high and low?

Over the past 52 weeks BNTX has traded between $79.52 and $124.00. The current price is 27.24% below its 52-week high.

Figures as of Nov 4, 2026. This information is provided for general purposes only and is not investment advice.